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This daily COVID-19 Health Evidence Summary is to signpost DFID and other UK government 
departments to the latest relevant evidence and discourse on COVID-19 to inform and support 
their response. It is a result of 3 hours of work and is not intended to be a comprehensive summary 
of available evidence on COVID-19 but aims to make original documents easily accessible to 
decision makers which, if relevant to them, they should go to before making decisions.   
 






















 This SR/meta-analysis looks at the 
psychiatric and neuropsychiatric 
consequences of coronavirus 
infections in 3,550 patients 
hospitalised with SARS, MERS and 
COVID-19 
 If infection with SARS-CoV-2 
follows a similar course to that with 
SARS-CoV or MERS-CoV, most 
patients should recover without 
experiencing mental illness 
 SARS-CoV-2 might cause delirium 
in a significant proportion of 
patients in the acute stage 
 Clinicians should be aware of the 
possibility of depression, anxiety, 
fatigue, post-traumatic stress 
disorder, and rarer neuropsychiatric 
syndromes in the longer term 
18.05.2020 A clinical risk 
score to identify 
patients with 
Covid-19 at high 






 This observational cohort study of 
1,157 patients acutely admitted to 
two London hospitals identified 
predictors of critical care admission 
and death in people admitted to 
hospital with COVID-19 and 
positive SARS-CoV-2 swab results 
2 
admission or 
death : an 
observational 
cohort study 
 These predictors were incorporated 
into a risk score that will inform 
clinical care and stratify patients for 
clinical trials 







infection in adults 
Annals of 
Internal 




 High-certainty evidence suggest 
that ACEI or ARB use is not 
associated with more severe 
COVID-19 disease 
 Moderate-certainty evidence 
suggests no association between 
use of these medications and 
positive SARS-CoV-2 test results 
among symptomatic patients 
 It remains uncertain whether these 
medications increase the risk for 
mild or asymptomatic disease or 
are beneficial in COVID-19 
treatment 






19.05.2020 Using a delay-
adjusted case 
fatality ratio to 
estimate under-
reporting 




(not yet peer 
reviewed) 
 Estimates of the percentage of 
symptomatic COVID-19 cases in 
different countries using case fatality 
ratio estimates based on data from 




the role of 






 Using a climate-dependent epidemic 
model to simulate the SARS-CoV-2 
pandemic outputs suggests that while 
variations in weather may be 
important for endemic infections, 
during the pandemic stage of an 
emerging pathogen the climate drives 
only modest changes to pandemic 
size 
 Results imply that both tropical and 
temperate locations should prepare 
for severe outbreaks of the diseases 
and that summertime temperatures 
will not effectively limit the spread of 
infection  
 Climate maybe important in the 
longer term where endemic cycles of 
the disease will likely be tied to 
3 
climate factors and seasonal peaks 
may vary with latitude  
15.05.2020 Inferring 
change points 







 This modelling approach allows 
detection and quantification of the 
effect of governmental interventions 
and forecasting future case number 
scenarios 
 Analysis highlights the importance of 
the precise timing and magnitude of 
interventions for future case numbers 
and the importance of including the 
reporting delay between the date of 
infection and the date of the 
confirmed cases in the model 
 The code is freely available and can 




















 The selection of patients for SARS-
CoV-2 screening remains challenging 
as many factors influence the decisions 
on which patients to screen, including 
test resources, test accuracy and local 
disease prevalence 
 Strategies are needed to best utilise 
testing resources 
 This retrospective study of patients 
screened between 12 March 2020 to 26 
March 2020 in the US found that 
exposure to confirmed SARS-CoV-2 
and recent travel were both significantly 
more predictive of a positive test than 
the presence of any symptoms 
suggesting a role for testing patients 



















 Reviewers identified two case studies 
and six small case series evaluating 
convalescent plasma for people with 
COVID-19 that included 32 
participants 
 All evidence was rated as very low 
certainty with a lack of higher-quality 
studies  
 It remains unclear whether these 
results are related to convalescent 
plasma therapy, to the underlying 
natural history of COVID-19, or to 
other concomitant treatments 
Comments, Editorials, Opinions, Blogs, News 
Publication 
date 
Title/URL Journal | Article type Author(s) 
19.05.2020 Update on the ongoing Novel 
Coronavirus (COVID-19) Global 
Epidemic, Brief #18 
Africa CDC  
18.05.2020 Planning for a COVID-19 vaccination 
program 





Linda Y. Fu 
18.05.2020 What can psychiatrists learn from 
SARS and MERS outbreaks?  
The Lancet Psychiatry 
| Comment 
Iris E Sommer 
P Roberto 
Bakker 
18.05.2020 Somalia sees “massive” rise in FGM 
during lockdown and Ramadan 
All Africa | News Emma Batha 
5 
15.05.2020 Wrong but useful – what Covid-19 
epidemiologic models can and cannot 
tell us 




15.05.2020 Drug researchers pursue new lines of 
attack against COVID-19 




12.05.2020 Neglected refugees find themselves 
even more neglected during COVID-
19 




Guidelines, Statements & Tools 
Publication 
Date 
Title/URL Source   Summary 








 Revised guidance accommodating 
new evidence 
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online brief with Dr 
David Nabarro 
Event 1h 4SD 
30.04.2020 Professor Chris 
Whitty’s Gresham 
lecture on COVID-19 
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Rapid review methodology 
The rapid daily search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa”) OR (“equity” OR “equities”) OR (“poverty”), restricted to 
articles published in the previous 2 to 3 days, in English. This is complemented by a search of the homepage of 
the following high-impact global health journals: The Lancet journals, New England Journal of Medicine, Nature, 
JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ Global Health, the PLoS journals and a Twitter 
search of their Twitter pages. A search also of preprints from bioRxiv and medRxiv. Please note that papers that 
have not been peer-reviewed are highlighted in red. All primary research papers that relate to the primary and 
secondary impacts of the COVID-19 response in LMICs, and disease control and health system responses are 
included. Articles related to tackling the secondary impacts on other sectors are not included. Additional 
commentaries, opinions, and commissioned pieces are selected based on relevance. 
The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
About this report 
This daily COVID-19 health evidence summary (HES) is based on 3 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before 
making decisions. The HES are not intended to replace medical or professional advice and the researcher or the 
K4D consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES 
alone. K4D services are provided by a consortium of leading organisations working in international development, 
led by the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds 
Nuffield Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), 
12 
University of Birmingham International Development Department (IDD) and the University of Manchester 
Humanitarian and Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Department for 
International Development (DFID) and its partners in support of pro-poor programmes. 
It is licensed for non-commercial purposes only. K4D cannot be held responsible for 
errors, omissions or any consequences arising from the use of information contained in 
this health evidence summary. Any views and opinions expressed do not necessarily 
reflect those of DFID, K4D or any other contributing organisation.  
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